Loading
The immune-related response criteria were the first rules to recognise that a tumour treated with immunotherapy can grow, or show new spots, before it responds.
Using phase 2 data on ipilimumab in advanced melanoma, Wolchok and colleagues (Clinical Cancer Research 2009) described four response patterns: shrinkage without new lesions; durable stable disease, sometimes followed by slow decline; response after an initial increase in tumour burden; and response in the presence of new lesions. All were associated with favourable survival. The immune-related response criteria were defined to capture the last two, which RECIST and WHO criteria would have called progression. iRECIST later took over this role in most trials.
Showing the technology this term belongs to: Immune checkpoint inhibitors.
Shares iRECIST (response criteria for immunotherapy trials), RECIST.
Shares iRECIST (response criteria for immunotherapy trials), Immune checkpoint inhibitors.
Shares iRECIST (response criteria for immunotherapy trials), Immune checkpoint inhibitors.
Shares iRECIST (response criteria for immunotherapy trials), RECIST.
Shares RECIST, Melanoma, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/